Cargando…
Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data
Cervical cancer is the fourth most common type of cancer in women worldwide. It is associated with a high death rate, despite the fact that it is a nearly 100% preventable disease because of very effective primary and secondary preventive strategies. Advanced and recurrent disease is uncurable with...
Autores principales: | Agostinelli, Veronica, Musacchio, Lucia, Camarda, Floriana, Salutari, Vanda, Carbone, Maria Vittoria, Ghizzoni, Viola, Nero, Camilla, Ricci, Caterina, Perri, Maria Teresa, Giudice, Elena, Lardino, Sara, Berardi, Rossana, Scambia, Giovanni, Lorusso, Domenica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543937/ https://www.ncbi.nlm.nih.gov/pubmed/37790898 http://dx.doi.org/10.2147/CMAR.S294080 |
Ejemplares similares
-
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022) -
PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022) -
Refining Adjuvant Therapy for Endometrial Cancer: New Standards and Perspectives
por: Giustozzi, Alessandra, et al.
Publicado: (2021) -
Tisotumab Vedotin Safety and Tolerability in Clinical Practice: Managing Adverse Events
por: Arn, Courtney R., et al.
Publicado: (2023) -
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?
por: Musacchio, L., et al.
Publicado: (2022)